What Lyophilization Technology does

Lyophilization Technology, Inc. (LTI) is a privately held, founder-owned Contract Development and Manufacturing Organization (CDMO) founded in 1992 by Edward H. Trappler and headquartered in Ivyland, Bucks County, Pennsylvania. The company operates as a focused specialist in pharmaceutical lyophilization (freeze-drying), offering an integrated service portfolio across three core lines: Development Sciences (product design, formulation development, low-temperature thermal analysis, cycle design and refinement, product characterization, pilot plant scale-up, and isolation/containment for hazardous materials), Clinical Manufacturing (aseptic filling and GMP-compliant manufacturing of Phase I/II clinical trial materials and toxicology batches up to 75L in vials, dual chamber cartridges, and syringes), and Technical Services (Fundamentals of Lyophilization training and consulting on equipment specifications, CMC submissions, process validation, and technology transfer). Proprietary technical differentiators include ControLyo controlled nucleation technology and dual chamber cartridge/syringe processing capabilities, supported by a patent granted in February 2022.

The firm's client base spans over 500 biotechnology and pharmaceutical organizations, ranging from virtual startups to large multinational corporations, with successful formulation work on more than 900 diverse products covering biologics, oncolytics, liposomes, peptides, proteins, vaccines, and controlled substances. The company maintains cGMP, ISO 5/Class 100, DEA, and BSL-2 certifications and serves both US and EU regulatory requirements. Revenue is generated through custom project-based pricing on multi-year contracts, with project oversight delivered through dedicated Project Directors under a direct enterprise sales model supplemented by active participation in industry conferences (BIO, AACR, PDA, DCAT, Interphex, ISPE). The 13+ named technical and operational leaders carry prior experience at major pharmaceutical firms including Merck, GlaxoSmithKline, AMRI, OsoBio, Catalent, and West Pharmaceuticals, and the company reports over 300 years of combined staff experience.

Name

Lyophilization Technology

Legal name

Lyophilization Technology, Inc.

Website

https://lyotechnology.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

Lyophilization Technology, Inc. is a privately held, founder-owned Pennsylvania-based CDMO specializing exclusively in pharmaceutical lyophilization, offering development sciences, GMP clinical manufacturing for Phase I/II trials, and technical consulting to over 500 biotech and pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO / Lyophilization Contract Manufacturing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Lyophilization (Freeze-Drying) CDMO (HLAGABAI)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Lyophilization development services
• Pharmaceutical freeze-drying
• Clinical trial manufacturing
• Formulation development
• Aseptic fill-finish

Headquarters

HQ city

Warminster

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Lyophilization Development Services: Comprehensive development sciences including product design, formulation development, thermal analysis, cycle design/refinement, product characterization, pilot plant scale-up, isolation/containment, and dual chamber cartridge/syringe processing. Services follow GMP principles with regulatory-ready documentation.
2. Clinical Trial Manufacturing: Aseptic filling and manufacturing of high-quality clinical trial materials including vaccines and parenteral injections for Phase I and II clinical trials. Services include toxicology material processing, aseptic vial/cartridge/syringe filling, compounding, and small-batch manufacturing up to 75L.
3. Technical Consulting and Training: Fundamentals of Lyophilization Training and consulting services for process optimization, equipment specifications, CMC regulatory submissions, technology transfer, process validation, and troubleshooting.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

Core offering

Lyophilization Technology, Inc. (LTI) is a Contract Development & Manufacturing Organization (CDMO) that provides specialized pharmaceutical lyophilization (freeze-drying) services for therapeutic and prophylactic injections, combination products, diagnostics, and medical devices. The company delivers three integrated service lines: Development Sciences (product design, formulation development, thermal analysis, cycle design, characterization, pilot scale-up, and containment), Clinical Manufacturing (aseptic filling and cGMP manufacturing of Phase I/II clinical trial materials and toxicology batches up to 75L), and Technical Services (Fundamentals of Lyophilization training and consulting for CMC, validation, technology transfer, and troubleshooting).

Product overview

Lyophilization Technology, Inc. (LTI) is a Contract Development & Manufacturing Organization (CDMO) specializing in all aspects of pharmaceutical lyophilization (freeze-drying). The company offers three core service lines: Development Sciences (product design, formulation development, thermal analysis, cycle design, product characterization, pilot scale-up, and containment services), Clinical Manufacturing (aseptic filling of clinical trial materials Phase I & II, toxicology materials, small-batch manufacturing up to 75L), and Technical Services (training courses and consulting). LTI processes products in various container configurations including vials, dual chamber cartridges and syringes. Key differentiators include ControLyo controlled nucleation technology, isolation/containment capabilities for highly potent compounds, and processing for biologics up to BSL-2. The company has served over 500 biotechnology and pharmaceutical organizations and completed successful formulations for over 900 diverse products.

Differentiator

Problem solved

Functional benefit

Products and services

• Development Sciences Comprehensive lyophilization development services including product design, formulation development, thermal analysis, cycle design/refinement, product characterization, and pilot plant scale-up, with isolation/containment capabilities for hazardous materials and dual chamber cartridge/syringe processing. Follows GMP principles with regulatory-ready documentation.
• Clinical Manufacturing Aseptic filling and manufacturing of clinical trial materials (Phase I & II) and toxicology materials, including processing in vials, dual chamber cartridges and syringes, small-batch manufacturing up to 75L, and ControLyo controlled nucleation technology. Fully cGMP compliant, meeting US and EU regulatory requirements.
• Technical Services Lyophilization training courses (Fundamentals of Lyophilization) and consulting services covering equipment specifications, CMC regulatory submissions, process validation, technology transfer, troubleshooting, batch record review, and compliance auditing.
• Product Design Defines desired attributes of the final lyophilized product through Target Product Profile (TPP) guidance, ensuring critical quality attributes (CQAs) are met for product suitability, manufacturing optimization, and stability.
• Formulation Development Develops product formulations based on physico-chemical requirements of active compounds, with successful formulations for biologics, oncolytics, liposomes, anti-infectives, peptides, proteins, vaccines, controlled substances, and highly potent compounds.
• Low Temperature Thermal Analysis (LT-TA) Thermal characterization of products using Freeze-Drying Microscopy (FDM), Electrical Resistance (ER), and Low Temperature Differential Scanning Calorimetry (LT-DSC) to quantify critical thermal transitions for freeze-drying optimization.
• Cycle Design / Optimization Establishes lyophilization processing procedures that are safe, effective, and robust for commercial manufacturing integration, including process refinement, troubleshooting, and technical transfer services.
• Product Characterization Evaluation of lyophilized finished products for critical quality attributes including physical inspection, reconstitution, pH measurement, osmolarity, Karl Fischer titration, thermogravimetric analysis, HT-DSC, and loss on drying.
• Pilot Plant Scale-up Transitions lyophilized products from small-scale laboratory production to larger-scale manufacturing using qualified pilot and small manufacturing lyophilizers with comprehensive automation and process monitoring.
• Isolation & Containment Handling of highly potent toxic and biohazardous materials using dedicated equipment, negative pressure isolators, disposable product contact surfaces, and personal protective equipment.
• Dual Chamber Cartridges & Syringes Processing Proprietary technology for filling and processing cartridge and syringe containers (single or double chamber) in both development laboratory and sterile suite environments for clinical trial material production.

Quantifiable outcome

• Over 500 biotechnology and pharmaceutical organizations served
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Recipharm: European-headquartered CDMO offering sterile fill-finish including lyophilization, serialization, and clinical through commercial manufacturing. Overlaps with LTI on lyophilization and clinical manufacturing but at much larger scale and with broader geographic footprint.
• Catalent: Global CDMO offering formulation, fill-finish (including lyophilization), and clinical/commercial manufacturing across multiple dosage forms and therapeutic areas. Overlaps directly with LTI on lyophilization services but at much larger scale and broader portfolio; Bob Cashman (LTI VP BD) is a former Catalent senior manager.
• Patheon (Thermo Fisher Scientific): One of the largest global CDMOs with extensive sterile fill-finish and lyophilization capacity for clinical and commercial supply. Competes with LTI for lyophilization development and CTM work but operates at a fundamentally different scale and breadth.
• Baxter BioPharma Solutions: Baxter's BioPharma Solutions business provides contract manufacturing services including lyophilization, sterile fill-finish, and prefilled syringe capabilities. A scale incumbent directly overlapping with LTI on lyophilized clinical and commercial parenteral manufacturing.

Direct peers

• Vibalogics: Specialized CDMO focused on virus, vaccine, and gene therapy manufacturing with strong lyophilization capabilities for live biological products. Comparable niche specialization to LTI in lyophilization for complex biologics, though with a virotherapy lean.
• Hovione: CDMO with strong expertise in pharmaceutical lyophilization, aseptic processing, and particle engineering for complex parenterals and inhaled drugs. Comparable to LTI in specialized formulation and lyophilization development capabilities, with somewhat broader service scope.
• Lyophilization Services of New England (LSNE): LSNE is a pure-play lyophilization CDMO offering development, aseptic fill-finish, and analytical services for parenteral pharmaceuticals. Directly comparable to LTI as a similarly specialized lyophilization-focused CDMO serving biotech and pharma clients across clinical and commercial phases.
• Alcami Corporation: US-based CDMO offering sterile fill-finish (including lyophilization), analytical services, and clinical manufacturing for small molecules and biologics. Closely comparable to LTI's clinical manufacturing, formulation development, and containment capabilities for early-phase programs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lyophilization-technology-inc

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyophilization Technology